Sign In

Login

Password

Forgot Password ? Sign Up

Vakcína proti chřipce (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vakcína proti chřipce" in Czech language version.

refsWebsite
Global rank Czech rank
96nih.gov
4th place
8th place
83doi.org
2nd place
4th place
66web.archive.org
1st place
1st place
36cdc.gov
218th place
304th place
25semanticscholar.org
11th place
313th place
20fda.gov
447th place
753rd place
20who.int
195th place
168th place
12europa.eu
68th place
38th place
4worldcat.org
5th place
3rd place
4clinicaltrials.gov
5,225th place
2,661st place
3publications.gc.ca
5,675th place
low place
3canada.ca
1,712th place
4,416th place
3umn.edu
1,266th place
2,040th place
3nytimes.com
7th place
43rd place
2harvard.edu
18th place
99th place
2seqirus.us
low place
low place
2thelancet.com
2,393rd place
974th place
1medicalxpress.com
8,255th place
77th place
1abc.net.au
139th place
475th place
1prnewswire.com
406th place
1,207th place
1drugs.com
399th place
1,058th place
1medicalnewstoday.com
3,011th place
1,266th place
1sanofi.us
low place
low place
1nhs.uk
1,989th place
1,996th place
1bbc.com
20th place
48th place
1theatlantic.com
228th place
622nd place
1reuters.com
49th place
92nd place
1sciencebasedmedicine.org
5,063rd place
8,162nd place
1cadth.ca
low place
low place
1tga.gov.au
3,984th place
low place
1zenodo.org
621st place
2,192nd place
1usnews.com
634th place
2,889th place
1phac-aspc.gc.ca
low place
low place
1archive.org
6th place
10th place
1astrazeneca.ca
low place
low place
1archive-it.org
910th place
1,741st place
1nbcnews.com
137th place
462nd place
1theguardian.com
12th place
39th place
1healthdirect.gov.au
low place
low place
1nsw.gov.au
640th place
2,906th place
1oecd.org
960th place
1,013th place
1npr.org
92nd place
367th place
1path.org
low place
low place
1virology.ws
low place
low place
1youtube.com
9th place
18th place
1seqirus.com
low place
low place
1ucl.ac.uk
1,306th place
3,266th place
1biospace.com
low place
low place
1biondvax.com
low place
low place
1drugtopics.com
low place
low place
1influenzareport.com
low place
low place
1uaeequafed.ae
low place
low place
1horsesport.org
low place
low place
1nationalhogfarmer.com
low place
low place
1knoxnews.com
3,504th place
low place
1latimes.com
22nd place
144th place
1washingtonpost.com
34th place
133rd place
1sahealth.sa.gov.au
low place
low place

abc.net.au

  • There's the option of a different flu jab this year — but it'll cost you $40. ABC News. 2021-03-26. Dostupné online [cit. 2021-11-16]. (anglicky) 

archive-it.org

wayback.archive-it.org

  • Fluzone, Fluzone High-Dose and Fluzone Intradermal [online]. July 11, 2017 [cit. 2020-06-01]. Dostupné v archivu pořízeném z originálu dne July 22, 2017. 

archive.org

astrazeneca.ca

  • Product Monograph: Flumist. [s.l.]: Astrazeneca Canada Inc., June 20, 2014. Dostupné online. 

bbc.com

  • Flu jab vital this winter along with Covid vaccine. BBC News. 2021-10-08. Dostupné online [cit. 2021-11-18]. (anglicky) 

biondvax.com

  • PHILLIPSON, Josh. BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate [online]. BiondVax. Dostupné online. 

biospace.com

  • KEOWN, Alex. FDA Approves Seqirus' Audenz as Vaccine Against Potential Flu Pandemic [online]. February 4, 2020 [cit. 2020-02-05]. Dostupné online. 

cadth.ca

  • Wells C, Grobelna A. High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Rapid Response Report. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), January 8, 2019. Dostupné online. ISSN 1922-8147. PMID 31141324. 

canada.ca

cdc.gov

  • 2015-2016 Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States | CDC. www.cdc.gov [online]. 2019-12-20 [cit. 2021-11-16]. Dostupné online. (anglicky) 
  • CDC. Benefits of Flu Vaccination During 2018-2019 Flu Season. Centers for Disease Control and Prevention [online]. 2020-01-16 [cit. 2021-11-16]. Dostupné online. (anglicky) 
  • CDC. Who Should and Who Should NOT Get Vaccinated. Centers for Disease Control and Prevention [online]. 2021-08-24 [cit. 2021-11-16]. Dostupné online. (anglicky) 
  • Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep. August 2021, s. 1–28. Dostupné online. DOI 10.15585/mmwr.rr7005a1. PMID 34448800. 
  • CDC. Flu Vaccine and People with Egg Allergies. Centers for Disease Control and Prevention [online]. 2020-09-22 [cit. 2021-11-16]. Dostupné online. (anglicky) 
  • https://www.cdc.gov/flu/prevent/qa_intradermal-vaccine.htm
  • TABLE 1. Influenza vaccines — United States, 2020–21 influenza season* | CDC. www.cdc.gov [online]. 2021-08-25 [cit. 2021-11-16]. Dostupné online. (anglicky) 
  • Cell-Based Flu Vaccines | CDC. www.cdc.gov [online]. 2021-05-06 [cit. 2021-11-17]. Dostupné online. (anglicky) 
  • CDC. What You Should Know for the 2018-2019 Influenza Season. Centers for Disease Control and Prevention [online]. 2019-04-08 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • CDC. Upcoming 2019-2020 Influenza Season. Centers for Disease Control and Prevention [online]. 2020-01-17 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • CDC. Key Facts About Seasonal Flu Vaccine. Centers for Disease Control and Prevention [online]. 2021-10-19 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Past Seasons Vaccine Effectiveness Estimates | CDC. www.cdc.gov [online]. 2021-08-26 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness – United States, February 2019. MMWR. Morbidity and Mortality Weekly Report. February 2019, s. 135–39. Dostupné online. DOI 10.15585/mmwr.mm6806a2. PMID 30763298. 
  • Seasonal Influenza Vaccine Effectiveness, 2018-2019. www.cdc.gov [online]. 2020-12-22 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. February 2020, s. 177–82. Dostupné online. DOI 10.15585/mmwr.mm6907a1. PMID 32078591. 
  • Summary of the 2007-2008 Influenza Season | CDC. www.cdc.gov [online]. 2019-05-14 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Vaccine Effectiveness: How Well Do Flu Vaccines Work? | CDC. www.cdc.gov [online]. 2021-10-25 [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Study of Flu-Related Deaths in Children Shows Healthy Children at Risk | CDC. www.cdc.gov [online]. 2019-03-11 [cit. 2021-11-19]. Dostupné online. (anglicky) 
  • Fluzone High-Dose Seasonal Influenza Vaccine | CDC. www.cdc.gov [online]. 2021-08-27 [cit. 2021-11-19]. Dostupné online. (anglicky) 
  • Flu shot [online]. 2020 [cit. 2020-09-24]. Dostupné online. 
  • Misconceptions about flu vaccines [online]. 2020 [cit. 2020-09-24]. Dostupné online. 
  • Thimerosal in Flu Vaccine [online]. October 16, 2015 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. 
  • Thimerosal in Vaccines Thimerosal – Concerns – Vaccine Safety [online]. October 27, 2015 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne November 2, 2019. 
  • Seasonal Flu Shot [online]. December 9, 2019 [cit. 2020-01-12]. Dostupné online. 
  • Children & Influenza (Flu) [online]. U.S. Centers for Disease Control and Prevention (CDC), October 23, 2019. Dostupné v archivu pořízeném z originálu dne November 11, 2019. 
  • Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) [online]. September 16, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 
  • Influenza Vaccination: A Summary for Clinicians – Health Professionals – Seasonal Influenza (Flu) [online]. U.S. Centers for Disease Control and Prevention (CDC), September 6, 2018. Dostupné v archivu pořízeném z originálu dne February 24, 2008. 
  • ((Centers for Disease Control Prevention (CDC))). Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season. Morbidity and Mortality Weekly Report (MMWR). December 2010, s. 1541–45. Dostupné v archivu pořízeném z originálu dne June 25, 2017. PMID 21124293. 
  • U.S. Centers for Disease Control and Prevention (CDC): ACIP votes down use of LAIV for 2016–2017 flu season, tisková zpráva, [cit. {{{accessdate}}}], Dostupné on-line.
  • Immunization Schedules [online]. U.S. Centers for Disease Control and Prevention (CDC) [cit. 2014-11-04]. Dostupné v archivu pořízeném z originálu dne November 5, 2014. 
  • ((Centers for Disease Control Prevention (CDC))). Update on influenza A (H1N1) 2009 monovalent vaccines. Morbidity and Mortality Weekly Report (MMWR). October 2009, s. 1100–01. Dostupné v archivu pořízeném z originálu dne June 29, 2011. PMID 19816398. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season. Morbidity and Mortality Weekly Report (MMWR). August 2011, s. 1073–77. Dostupné v archivu pořízeném z originálu dne May 25, 2017. PMID 21849963. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel: 2011–12 influenza season, United States. Morbidity and Mortality Weekly Report (MMWR). September 2012, s. 753–57. Dostupné v archivu pořízeném z originálu dne June 24, 2017. PMID 23013720. 
  • How Influenza (Flu) Vaccines Are Made [online]. U.S. Centers for Disease Control and Prevention (CDC), November 26, 2019 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. 
  • Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 Influenza Season. MMWR. Recommendations and Reports. August 2017, s. 1–20. Dostupné online. DOI 10.15585/mmwr.rr6602a1. PMID 28841201. 
  • Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness – United States, February 2018. MMWR. Morbidity and Mortality Weekly Report. February 2018, s. 180–85. Dostupné online. DOI 10.15585/mmwr.mm6706a2. PMID 29447141. 

clinicaltrials.gov

  • NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID). An Open-Label, Randomized Phase I Study in Healthy Adults of 4 Prime-Boost Schedules With Monovalent Influenza Subunit Virion (H5N1) Vaccine (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine (VRC, NIAID). [s.l.]: [s.n.] Dostupné online. Submitted: October 18, 2008. 
  • NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID). VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine. [s.l.]: [s.n.] Dostupné online. Submitted: March 12, 2010. 
  • NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID). A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine. [s.l.]: [s.n.] Dostupné online. Submitted: February 9, 2017. 
  • BIONDVAX PHARMACEUTICALS LTD. A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).. [s.l.]: [s.n.] Dostupné online. Submitted: February 8, 2018. 

doi.org

dx.doi.org

  • Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Human Vaccines & Immunotherapeutics. July 2012, s. 851–62. DOI 10.4161/hv.19917. PMID 22777099. 
  • Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews. February 2018, s. CD001269. DOI 10.1002/14651858.CD001269.pub6. PMID 29388196. 
  • Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. January 2012, s. 36–44. DOI 10.1016/S1473-3099(11)70295-X. PMID 22032844. 
  • Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, Rivetti A. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews. February 2018, s. CD004876. DOI 10.1002/14651858.CD004876.pub4. PMID 29388197. 
  • Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep. August 2021, s. 1–28. Dostupné online. DOI 10.15585/mmwr.rr7005a1. PMID 34448800. 
  • [s.l.]: [s.n.] ISBN 978-0-309-09504-4. DOI 10.17226/11150. 
  • Milián E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015, s. 504831. DOI 10.1155/2015/504831. PMID 25815321. 
  • Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLOS ONE. December 2010, s. e15559. DOI 10.1371/journal.pone.0015559. PMID 21203523. Bibcode 2010PLoSO...515559L. 
  • Osterholm MT. Preparing for the next pandemic. The New England Journal of Medicine. May 2005, s. 1839–42. DOI 10.1056/NEJMp058068. PMID 15872196. 
  • McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clinical Infectious Diseases. June 2010, s. 1487–92. DOI 10.1086/652441. PMID 20415539. 
  • Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. January 2012, s. 36–44. DOI 10.1016/s1473-3099(11)70295-x. PMID 22032844. 
  • MACINTYRE, CR; MAHIMBO, A; MOA, AM; BARNES, M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction.. Heart (British Cardiac Society). December 15, 2016, s. 1953–56. DOI 10.1136/heartjnl-2016-309983. PMID 27686519. 
  • Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness – United States, February 2019. MMWR. Morbidity and Mortality Weekly Report. February 2019, s. 135–39. Dostupné online. DOI 10.15585/mmwr.mm6806a2. PMID 30763298. 
  • Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. February 2020, s. 177–82. Dostupné online. DOI 10.15585/mmwr.mm6907a1. PMID 32078591. 
  • Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. Journal of Virology. May 2006, s. 4962–70. DOI 10.1128/JVI.80.10.4962-4970.2006. PMID 16641287. 
  • Jefferson T. Influenza vaccination: policy versus evidence. BMJ. October 2006, s. 912–15. DOI 10.1136/bmj.38995.531701.80. PMID 17068038. 
  • CARRAT, F.; FLAHAULT, A. Influenza vaccine: The challenge of antigenic drift. Vaccine. September 28, 2007, s. 6852–62. ISSN 0264-410X. DOI 10.1016/j.vaccine.2007.07.027. PMID 17719149. 
  • Ramsay LC, Buchan SA, Stirling RG, Cowling BJ, Feng S, Kwong JC, Warshawsky BF. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. January 2019, s. 9. DOI 10.1186/s12916-018-1239-8. PMID 30626399. 
  • Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. July 2017, s. 723–36. DOI 10.1080/14760584.2017.1334554. PMID 28562111. 
  • Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews. February 2018, s. CD004879. DOI 10.1002/14651858.CD004879.pub5. PMID 29388195. 
  • PELEG, Noam; ZEVIT, Noam; SHAMIR, Raanan; CHODICK, Gabriel; LEVY, Itzhak. Seasonal influenza vaccination rates and reasons for non-vaccination in children with gastrointestinal disorders. Vaccine. January 2015, s. 182–86. DOI 10.1016/j.vaccine.2014.10.086. PMID 25444802. 
  • Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, Hawker J. Vaccinating healthcare workers against influenza to protect the vulnerable – is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine. May 2006, s. 4212–21. DOI 10.1016/j.vaccine.2005.12.043. PMID 16546308. 
  • Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. Clinical Infectious Diseases. January 2014, s. 50–57. DOI 10.1093/cid/cit580. PMID 24046301. 
  • Griffin MR. Influenza vaccination of healthcare workers: making the grade for action. Clinical Infectious Diseases. January 2014, s. 58–60. DOI 10.1093/cid/cit590. PMID 24046312. 
  • Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L. Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine. October 2009, s. 6300–04. DOI 10.1016/j.vaccine.2009.07.008. PMID 19840664. 
  • Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. The Lancet. Infectious Diseases. December 2014, s. 1228–39. DOI 10.1016/S1473-3099(14)70960-0. PMID 25455990. 
  • Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. The New England Journal of Medicine. October 2007, s. 1373–81. Dostupné online. DOI 10.1056/NEJMoa070844. PMID 17914038. S2CID 14850833. 
  • Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. The Lancet. Infectious Diseases. October 2007, s. 658–66. DOI 10.1016/S1473-3099(07)70236-0. PMID 17897608. 
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. January 2003, s. 179–86. DOI 10.1001/jama.289.2.179. PMID 12517228. S2CID 5018362. 
  • DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine. August 2014, s. 635–45. Dostupné online. DOI 10.1056/NEJMoa1315727. PMID 25119609. S2CID 205096393. 
  • Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Human Vaccines & Immunotherapeutics. 2015, s. 553–63. DOI 10.1080/21645515.2015.1011562. PMID 25714138. 
  • Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infectious Diseases. May 2010, s. 134. DOI 10.1186/1471-2334-10-134. PMID 20504306. 
  • Haverkate M, D'Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, Appelgren E, ((VENICE project gatekeepers contact points)). Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Euro Surveillance. May 2012. DOI 10.2807/ese.17.22.20183-en. PMID 22687916. 
  • Kassianos G. Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement. Drugs in Context. 2015, s. 212268. DOI 10.7573/dic.212268. PMID 25657810. 
  • Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. The Cochrane Database of Systematic Reviews. June 2016, s. CD005187. DOI 10.1002/14651858.CD005187.pub5. PMID 27251461. 
  • Fell DB, Sprague AE, Liu N, Yasseen AS, Wen SW, Smith G, Walker MC. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American Journal of Public Health. June 2012, s. e33–40. DOI 10.2105/AJPH.2011.300606. PMID 22515877. 
  • Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simões EA, Klugman KP, Nunes MC. Influenza vaccination of pregnant women and protection of their infants. The New England Journal of Medicine. September 2014, s. 918–31. DOI 10.1056/NEJMoa1401480. PMID 25184864. 
  • Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Safety. 2009, s. 309–23. DOI 10.2165/00002018-200932040-00005. PMID 19388722. S2CID 33670594. 
  • Reorganized text. JAMA Otolaryngology–Head & Neck Surgery. May 2015, s. 428. DOI 10.1001/jama.248.6.698. PMID 25996397. 
  • Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. American Journal of Epidemiology. February 2009, s. 382–88. DOI 10.1093/aje/kwn310. PMID 19033158. 
  • Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphaël JC, Gaillard JL, Gault E. Guillain-Barré syndrome and influenza virus infection. Clinical Infectious Diseases. January 2009, s. 48–56. DOI 10.1086/594124. PMID 19025491. 
  • Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. March 2009, s. 2114–20. Dostupné online. DOI 10.1016/j.vaccine.2009.01.125. PMID 19356614. 
  • Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. December 2015, s. h6291. DOI 10.1136/bmj.h6291. PMID 26645895. 
  • Greenhawt M. Live attenuated influenza vaccine for children with egg allergy. BMJ. December 2015, s. h6656. DOI 10.1136/bmj.h6656. PMID 26657778. S2CID 37037904. 
  • YONG, Ed. Narcolepsy confirmed as autoimmune disease. Nature. 2013. DOI 10.1038/nature.2013.14413. S2CID 74850662. 
  • Offit PA. Thimerosal and vaccines – a cautionary tale. The New England Journal of Medicine. September 2007, s. 1278–79. Dostupné online. DOI 10.1056/NEJMp078187. PMID 17898096. S2CID 36318722. 
  • To KW, Lai A, Lee KC, Koh D, Lee SS. Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions. The Journal of Hospital Infection. October 2016, s. 133–42. DOI 10.1016/j.jhin.2016.07.003. PMID 27546456. 
  • Rubin GJ, Potts HW, Michie S. Likely uptake of swine and seasonal flu vaccines among healthcare workers. A cross-sectional analysis of UK telephone survey data. Vaccine. March 2011, s. 2421–28. DOI 10.1016/j.vaccine.2011.01.035. PMID 21277402. 
  • Lee JK, Lam GK, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. May 2018, s. 435–443. DOI 10.1080/14760584.2018.1471989. PMID 29715054. S2CID 21688517. 
  • Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone High-Dose Influenza Vaccine. Expert Rev Vaccines. December 2016, s. 1495–1505. DOI 10.1080/14760584.2016.1254044. PMID 27813430. 
  • Han YK, Michie S, Potts HW, Rubin GJ. Predictors of influenza vaccine uptake during the 2009/10 influenza A H1N1v ('swine flu') pandemic: Results from five national surveys in the United Kingdom. Preventive Medicine. March 2016, s. 57–61. DOI 10.1016/j.ypmed.2015.12.018. PMID 26757401. 
  • Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine. September 2011, s. 6472–84. DOI 10.1016/j.vaccine.2011.06.107. PMID 21756960. 
  • Brien S, Kwong JC, Buckeridge DL. The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine. February 2012, s. 1255–64. DOI 10.1016/j.vaccine.2011.12.089. PMID 22214889. 
  • Thomas RE, Lorenzetti DL. Interventions to increase influenza vaccination rates of those 60 years and older in the community. The Cochrane Database of Systematic Reviews. May 2018, s. CD005188. DOI 10.1002/14651858.CD005188.pub4. PMID 29845606. 
  • Amodio E, Anastasi G, Marsala MG, Torregrossa MV, Romano N, Firenze A. Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy). Vaccine. February 2011, s. 1408–12. DOI 10.1016/j.vaccine.2010.12.041. PMID 21199700. 
  • Chor JS, Ngai KL, Goggins WB, Wong MC, Wong SY, Lee N, Leung TF, Rainer TH, Griffiths S, Chan PK. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ. August 2009, s. b3391. DOI 10.1136/bmj.b3391. PMID 19706937. 
  • Bull AL, Bennett N, Pitcher HC, Russo PL, Richards MJ. Influenza vaccine coverage among health care workers in Victorian public hospitals. The Medical Journal of Australia. February 2007, s. 185–86. Dostupné online. DOI 10.5694/j.1326-5377.2007.tb00858.x. PMID 17309419. S2CID 25091208. 
  • Abbasi J. The Search for a Universal Flu Vaccine Heats Up. JAMA. November 2019, s. 1942–1944. DOI 10.1001/jama.2019.16816. PMID 31693060. S2CID 207903441. 
  • Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. May 2007, s. 3871–78. DOI 10.1016/j.vaccine.2007.01.106. PMID 17337102. 
  • Postma MJ, Baltussen RP, Palache AM, Wilschut JC. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. April 2006, s. 215–27. DOI 10.1586/14737167.6.2.215. PMID 20528557. S2CID 12765724. 
  • Newall AT, Kelly H, Harsley S, Scuffham PA. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. PharmacoEconomics. 2009, s. 439–50. DOI 10.2165/00019053-200927060-00001. PMID 19640008. S2CID 20855671. 
  • Newall AT, Viboud C, Wood JG. Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiology and Infection. June 2010, s. 836–42. Dostupné online. DOI 10.1017/S095026880999118X. PMID 19941685. S2CID 29939376. 
  • Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. PharmacoEconomics. August 2013, s. 693–702. DOI 10.1007/s40273-013-0060-7. PMID 23645539. S2CID 8616720. 
  • Newall AT, Scuffham PA. Uncertainty and variability in influenza cost-effectiveness models. Australian and New Zealand Journal of Public Health. December 2011, s. 576; author reply 576–77. DOI 10.1111/j.1753-6405.2011.00788.x. PMID 22151168. S2CID 22402257. 
  • Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations. Drugs. January 2012, s. 35–48. DOI 10.2165/11597310-000000000-00000. PMID 22191794. S2CID 46305863. 
  • Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. PharmacoEconomics. August 2012, s. 647–60. DOI 10.2165/11599130-000000000-00000. PMID 22788257. S2CID 38289883. 
  • Newall AT, Wood JG, Oudin N, MacIntyre CR. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerging Infectious Diseases. February 2010, s. 224–30. DOI 10.3201/eid1602.090571. PMID 20113551. 
  • Lampos V, Yom-Tov E, Pebody R, Cox IJ. Assessing the impact of a health intervention via user-generated Internet content. Data Mining and Knowledge Discovery. 2015, s. 1434–57. Dostupné online. DOI 10.1007/s10618-015-0427-9. S2CID 215415165. 
  • Wagner M, Lampos V, Yom-Tov E, Pebody R, Cox IJ. Estimating the Population Impact of a New Pediatric Influenza Vaccination Program in England Using Social Media Content. Journal of Medical Internet Research. December 2017, s. e416. DOI 10.2196/jmir.8184. PMID 29269339. 
  • Cho A, Wrammert J. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Current Opinion in Virology. April 2016, s. 110–115. DOI 10.1016/j.coviro.2016.03.002. PMID 27031684. 
  • OCUNO, Y. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.. Journal of Virology. May 1993, s. 2552–58. DOI 10.1128/JVI.67.5.2552-2558.1993. PMID 7682624. 
  • Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. European Journal of Pharmaceutics and Biopharmaceutics. August 2015, s. 251–63. DOI 10.1016/j.ejpb.2015.05.023. PMID 26047796. 
  • Deng L, Cho KJ, Fiers W, Saelens X. M2e-Based Universal Influenza A Vaccines. Vaccines. February 2015, s. 105–36. DOI 10.3390/vaccines3010105. PMID 26344949. 
  • Gottlieb T, Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. Journal of Autoimmunity. November 2014, s. 15–20. DOI 10.1016/j.jaut.2014.07.005. PMID 25172355. 
  • Toussi DN, Massari P. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines. April 2014, s. 323–53. DOI 10.3390/vaccines2020323. PMID 26344622. 
  • Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. October 2014, s. 5816–23. DOI 10.1016/j.vaccine.2014.08.031. PMID 25173483. 
  • van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, Frijlink HW, Hak E. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol. Medicine (Baltimore). March 2017, s. e6339. DOI 10.1097/MD.0000000000006339. PMID 28296763. 
  • FAST, Patricia E; COX, Josephine H. An influenza vaccine pill-can we swallow it?. The Lancet Infectious Diseases. September 1, 2015, s. 1051–6; discussion 1056–57. Dostupné online [cit. January 27, 2020]. DOI 10.1016/s1473-3099(15)00252-2. PMID 2633331. 
  • LIEBOWITZ, David; GOTTLIEB, Keith; KOLHATKAR, Nikita S; GARG, Shaily J; ASHER, Jason M; NAZARENO, Jonathan. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. The Lancet Infectious Diseases. Elsevier, January 21, 2020, s. 435–444. Dostupné online [cit. January 27, 2020]. DOI 10.1016/S1473-3099(19)30584-5. PMID 31978354. S2CID 210892802. 
  • Yen HL, Peiris JS. Virology: bird flu in mammals. Nature. May 2012, s. 332–33. DOI 10.1038/nature11192. PMID 22722190. S2CID 205229301. Bibcode 2012Natur.486..332Y. 
  • Karaca K, Dubovi EJ, Siger L, Robles A, Audonnet JC, Jiansheng Y, Nordgren R, Minke JM. Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs. American Journal of Veterinary Research. February 2007, s. 208–12. DOI 10.2460/ajvr.68.2.208. PMID 17269888. 
  • Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 Influenza Season. MMWR. Recommendations and Reports. August 2017, s. 1–20. Dostupné online. DOI 10.15585/mmwr.rr6602a1. PMID 28841201. 
  • Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness – United States, February 2018. MMWR. Morbidity and Mortality Weekly Report. February 2018, s. 180–85. Dostupné online. DOI 10.15585/mmwr.mm6706a2. PMID 29447141. 

drugs.com

drugtopics.com

  • SEDERSTROM, Jill. Researchers Exploring Oral Flu Vaccine and Treatment Options [online]. Drug Topics, July 19, 2019 [cit. 2020-01-27]. Dostupné online. 

europa.eu

ema.europa.eu

  • https://www.ema.europa.eu/en/medicines/human/EPAR/supemtek
  • Fluad Tetra EPAR [online]. March 24, 2020 [cit. 2020-05-29]. Dostupné online. 
  • Supemtek: Pending EC decision [online]. September 17, 2020 [cit. 2020-09-21]. Dostupné online. 
  • EU recommendations for 2019/2020 seasonal flu vaccine composition [online]. May 15, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • EU recommendations for 2020/2021 seasonal flu vaccine composition [online]. April 1, 2020. Dostupné online. 
  • EU recommendations for 2021/2022 seasonal flu vaccine composition [online]. March 30, 2021. Dostupné online. 
  • Archivovaná kopie. www.ema.europa.eu [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném z originálu dne 2021-06-30. 

ecdc.europa.eu

fda.gov

  • FDA approves first quadrivalent vaccine to prevent seasonal influenza. web.archive.org [online]. 2012-12-21 [cit. 2021-11-18]. Dostupné v archivu pořízeném z originálu dne 2012-12-21. 
  • Dostupné online. 
  • RESEARCH, Center for Biologics Evaluation and. Fluzone Quadrivalent, Fluzone High-Dose Quadrivalent, Fluzone, Intradermal Quadrivalent, Fluzone Quadrivalent Southern Hemisphere. FDA. 2021-09-27. Dostupné online [cit. 2021-11-18]. (anglicky) 
  • RESEARCH, Center for Biologics Evaluation and. FLUAD QUADRIVALENT. FDA. 2021-07-06. Dostupné online [cit. 2021-11-18]. (anglicky) 
  • RESEARCH, Center for Biologics Evaluation and. Fluzone Quadrivalent, Fluzone High-Dose Quadrivalent, Fluzone, Intradermal Quadrivalent, Fluzone Quadrivalent Southern Hemisphere. FDA. 2021-09-27. Dostupné online [cit. 2021-11-19]. (anglicky) 
  • RESEARCH, Center for Biologics Evaluation and. Afluria Quadrivalent, Afluria Quadrivalent Southern Hemisphere. FDA. 2021-07-06. Dostupné online [cit. 2021-11-19]. (anglicky) 
  • FDA approves first seasonal influenza vaccine containing an adjuvant. web.archive.org [online]. 2017-07-22 [cit. 2021-11-20]. Dostupné v archivu pořízeném z originálu dne 2017-07-22. 
  • RESEARCH, Center for Biologics Evaluation and. FLUAD. FDA. 2021-07-06. Dostupné online [cit. 2021-11-19]. (anglicky) 
  • Fluad [online]. November 8, 2019 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. STN 125510. 
  • Fluzone, Fluzone High-Dose and Fluzone Intradermal [online]. July 11, 2017 [cit. 2020-06-01]. Dostupné v archivu pořízeném z originálu dne July 22, 2017. 
  • RESEARCH, Center for Biologics Evaluation and. Approved Products – November 20, 2012 Approval Letter – Flucelvax [online]. U.S. Food and Drug Administration (FDA). Dostupné v archivu pořízeném z originálu dne December 3, 2012. 
  • Flublok [online]. February 26, 2018 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. STN 125285. 
  • Flublok Quadrivalent [online]. August 2, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. STN 125285. 
  • FDA Approves Vaccines for 2009 H1N1 Influenza Virus. web.archive.org [online]. 2009-10-15 [cit. 2021-11-20]. Dostupné v archivu pořízeném z originálu dne 2009-10-15. 
  • Audenz [online]. January 31, 2020 [cit. 2020-02-05]. Dostupné online. STN: 125692. 
  • Influenza Virus Vaccine for the 2018–2019 Season [online]. November 8, 2018 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Influenza Vaccine for the 2019-2020 Season [online]. December 5, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Vaccines and Related Biological Products Advisory Committee March 6–7, 2019 Meeting Announcement [online]. March 6–7, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Vaccines and Related Biological Products Advisory Committee March 22, 2019 Meeting Announcement [online]. March 22, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Influenza Vaccine for the 2020-2021 Season [online]. July 10, 2020 [cit. 2020-07-12]. Dostupné online. 

harvard.edu

adsabs.harvard.edu

healthdirect.gov.au

  • Flu vaccine FAQs [online]. Healthdirect, Department of Health, Government of Australia, April 1, 2019 [cit. 2019-05-29]. Dostupné online. 

horsesport.org

influenzareport.com

knoxnews.com

latimes.com

  • KARLAMANGLA, Soumya. Severe flu brings medicine shortages, packed ERs and a rising death toll in California. Los Angeles Times. January 6, 2018. Dostupné online [cit. January 7, 2018]. 

medicalnewstoday.com

  • First Quadrivalent Vaccine Against Seasonal Flu Wins FDA Approval. www.medicalnewstoday.com [online]. 2012-03-02 [cit. 2021-11-18]. Dostupné online. (anglicky) 

medicalxpress.com

nationalhogfarmer.com

  • Swine Flu Virus Turns Endemic [online]. September 15, 2007. Dostupné v archivu pořízeném z originálu dne April 29, 2009. 

nbcnews.com

  • TANNER, Lindsey. Hospitals crack down on workers who refuse flu shots [online]. NBC News, January 13, 2013 [cit. 2014-07-24]. Dostupné v archivu pořízeném z originálu dne December 3, 2013. 

nhs.uk

  • Flu vaccine. nhs.uk [online]. 2019-07-31 [cit. 2021-11-18]. Dostupné online. (anglicky) 

nih.gov

ncbi.nlm.nih.gov

  • Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Human Vaccines & Immunotherapeutics. July 2012, s. 851–62. DOI 10.4161/hv.19917. PMID 22777099. 
  • Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews. February 2018, s. CD001269. DOI 10.1002/14651858.CD001269.pub6. PMID 29388196. 
  • Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. January 2012, s. 36–44. DOI 10.1016/S1473-3099(11)70295-X. PMID 22032844. 
  • Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, Rivetti A. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews. February 2018, s. CD004876. DOI 10.1002/14651858.CD004876.pub4. PMID 29388197. 
  • Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep. August 2021, s. 1–28. Dostupné online. DOI 10.15585/mmwr.rr7005a1. PMID 34448800. 
  • Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Annals of the Academy of Medicine, Singapore. June 2008, s. 510–17. PMID 18618064. 
  • Milián E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015, s. 504831. DOI 10.1155/2015/504831. PMID 25815321. 
  • Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLOS ONE. December 2010, s. e15559. DOI 10.1371/journal.pone.0015559. PMID 21203523. Bibcode 2010PLoSO...515559L. 
  • Osterholm MT. Preparing for the next pandemic. The New England Journal of Medicine. May 2005, s. 1839–42. DOI 10.1056/NEJMp058068. PMID 15872196. 
  • McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clinical Infectious Diseases. June 2010, s. 1487–92. DOI 10.1086/652441. PMID 20415539. 
  • Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. January 2012, s. 36–44. DOI 10.1016/s1473-3099(11)70295-x. PMID 22032844. 
  • MACINTYRE, CR; MAHIMBO, A; MOA, AM; BARNES, M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction.. Heart (British Cardiac Society). December 15, 2016, s. 1953–56. DOI 10.1136/heartjnl-2016-309983. PMID 27686519. 
  • Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness – United States, February 2019. MMWR. Morbidity and Mortality Weekly Report. February 2019, s. 135–39. Dostupné online. DOI 10.15585/mmwr.mm6806a2. PMID 30763298. 
  • Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. February 2020, s. 177–82. Dostupné online. DOI 10.15585/mmwr.mm6907a1. PMID 32078591. 
  • Fedson DS. Measuring protection: efficacy versus effectiveness. Developments in Biological Standardization. 1998, s. 195–201. PMID 9855432. 
  • Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. Journal of Virology. May 2006, s. 4962–70. DOI 10.1128/JVI.80.10.4962-4970.2006. PMID 16641287. 
  • Jefferson T. Influenza vaccination: policy versus evidence. BMJ. October 2006, s. 912–15. DOI 10.1136/bmj.38995.531701.80. PMID 17068038. 
  • CARRAT, F.; FLAHAULT, A. Influenza vaccine: The challenge of antigenic drift. Vaccine. September 28, 2007, s. 6852–62. ISSN 0264-410X. DOI 10.1016/j.vaccine.2007.07.027. PMID 17719149. 
  • Ramsay LC, Buchan SA, Stirling RG, Cowling BJ, Feng S, Kwong JC, Warshawsky BF. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. January 2019, s. 9. DOI 10.1186/s12916-018-1239-8. PMID 30626399. 
  • Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. July 2017, s. 723–36. DOI 10.1080/14760584.2017.1334554. PMID 28562111. 
  • Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews. February 2018, s. CD004879. DOI 10.1002/14651858.CD004879.pub5. PMID 29388195. 
  • PELEG, Noam; ZEVIT, Noam; SHAMIR, Raanan; CHODICK, Gabriel; LEVY, Itzhak. Seasonal influenza vaccination rates and reasons for non-vaccination in children with gastrointestinal disorders. Vaccine. January 2015, s. 182–86. DOI 10.1016/j.vaccine.2014.10.086. PMID 25444802. 
  • Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, Hawker J. Vaccinating healthcare workers against influenza to protect the vulnerable – is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine. May 2006, s. 4212–21. DOI 10.1016/j.vaccine.2005.12.043. PMID 16546308. 
  • Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. Clinical Infectious Diseases. January 2014, s. 50–57. DOI 10.1093/cid/cit580. PMID 24046301. 
  • Griffin MR. Influenza vaccination of healthcare workers: making the grade for action. Clinical Infectious Diseases. January 2014, s. 58–60. DOI 10.1093/cid/cit590. PMID 24046312. 
  • Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L. Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine. October 2009, s. 6300–04. DOI 10.1016/j.vaccine.2009.07.008. PMID 19840664. 
  • Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. The Lancet. Infectious Diseases. December 2014, s. 1228–39. DOI 10.1016/S1473-3099(14)70960-0. PMID 25455990. 
  • Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. The New England Journal of Medicine. October 2007, s. 1373–81. Dostupné online. DOI 10.1056/NEJMoa070844. PMID 17914038. S2CID 14850833. 
  • Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. The Lancet. Infectious Diseases. October 2007, s. 658–66. DOI 10.1016/S1473-3099(07)70236-0. PMID 17897608. 
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. January 2003, s. 179–86. DOI 10.1001/jama.289.2.179. PMID 12517228. S2CID 5018362. 
  • DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine. August 2014, s. 635–45. Dostupné online. DOI 10.1056/NEJMoa1315727. PMID 25119609. S2CID 205096393. 
  • Wells C, Grobelna A. High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Rapid Response Report. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), January 8, 2019. Dostupné online. ISSN 1922-8147. PMID 31141324. 
  • Mascagni P, Vicenzi E, Kajaste-Rudnitski A, Pellicciotta G, Monti A, Cervi C, Vitalucci R, Toffoletto F. Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers. La Medicina del Lavoro. 2012, s. 220–29. PMID 22838300. 
  • Influenza vaccine with squalene adjuvant: new preparation. No better than available products. Prescrire International. December 2004, s. 206–08. PMID 15599987. 
  • Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Human Vaccines & Immunotherapeutics. 2015, s. 553–63. DOI 10.1080/21645515.2015.1011562. PMID 25714138. 
  • Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infectious Diseases. May 2010, s. 134. DOI 10.1186/1471-2334-10-134. PMID 20504306. 
  • Haverkate M, D'Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, Appelgren E, ((VENICE project gatekeepers contact points)). Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Euro Surveillance. May 2012. DOI 10.2807/ese.17.22.20183-en. PMID 22687916. 
  • Field RI. Mandatory vaccination of health care workers: whose rights should come first?. P & T. November 2009, s. 615–18. PMID 20140133. 
  • Kassianos G. Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement. Drugs in Context. 2015, s. 212268. DOI 10.7573/dic.212268. PMID 25657810. 
  • Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. The Cochrane Database of Systematic Reviews. June 2016, s. CD005187. DOI 10.1002/14651858.CD005187.pub5. PMID 27251461. 
  • Fell DB, Sprague AE, Liu N, Yasseen AS, Wen SW, Smith G, Walker MC. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American Journal of Public Health. June 2012, s. e33–40. DOI 10.2105/AJPH.2011.300606. PMID 22515877. 
  • Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simões EA, Klugman KP, Nunes MC. Influenza vaccination of pregnant women and protection of their infants. The New England Journal of Medicine. September 2014, s. 918–31. DOI 10.1056/NEJMoa1401480. PMID 25184864. 
  • Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Safety. 2009, s. 309–23. DOI 10.2165/00002018-200932040-00005. PMID 19388722. S2CID 33670594. 
  • Reorganized text. JAMA Otolaryngology–Head & Neck Surgery. May 2015, s. 428. DOI 10.1001/jama.248.6.698. PMID 25996397. 
  • Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. American Journal of Epidemiology. February 2009, s. 382–88. DOI 10.1093/aje/kwn310. PMID 19033158. 
  • Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphaël JC, Gaillard JL, Gault E. Guillain-Barré syndrome and influenza virus infection. Clinical Infectious Diseases. January 2009, s. 48–56. DOI 10.1086/594124. PMID 19025491. 
  • Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. March 2009, s. 2114–20. Dostupné online. DOI 10.1016/j.vaccine.2009.01.125. PMID 19356614. 
  • Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. December 2015, s. h6291. DOI 10.1136/bmj.h6291. PMID 26645895. 
  • Greenhawt M. Live attenuated influenza vaccine for children with egg allergy. BMJ. December 2015, s. h6656. DOI 10.1136/bmj.h6656. PMID 26657778. S2CID 37037904. 
  • Offit PA. Thimerosal and vaccines – a cautionary tale. The New England Journal of Medicine. September 2007, s. 1278–79. Dostupné online. DOI 10.1056/NEJMp078187. PMID 17898096. S2CID 36318722. 
  • To KW, Lai A, Lee KC, Koh D, Lee SS. Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions. The Journal of Hospital Infection. October 2016, s. 133–42. DOI 10.1016/j.jhin.2016.07.003. PMID 27546456. 
  • Rubin GJ, Potts HW, Michie S. Likely uptake of swine and seasonal flu vaccines among healthcare workers. A cross-sectional analysis of UK telephone survey data. Vaccine. March 2011, s. 2421–28. DOI 10.1016/j.vaccine.2011.01.035. PMID 21277402. 
  • Lee JK, Lam GK, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. May 2018, s. 435–443. DOI 10.1080/14760584.2018.1471989. PMID 29715054. S2CID 21688517. 
  • Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone High-Dose Influenza Vaccine. Expert Rev Vaccines. December 2016, s. 1495–1505. DOI 10.1080/14760584.2016.1254044. PMID 27813430. 
  • ((Centers for Disease Control Prevention (CDC))). Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season. Morbidity and Mortality Weekly Report (MMWR). December 2010, s. 1541–45. Dostupné v archivu pořízeném z originálu dne June 25, 2017. PMID 21124293. 
  • Han YK, Michie S, Potts HW, Rubin GJ. Predictors of influenza vaccine uptake during the 2009/10 influenza A H1N1v ('swine flu') pandemic: Results from five national surveys in the United Kingdom. Preventive Medicine. March 2016, s. 57–61. DOI 10.1016/j.ypmed.2015.12.018. PMID 26757401. 
  • Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine. September 2011, s. 6472–84. DOI 10.1016/j.vaccine.2011.06.107. PMID 21756960. 
  • Brien S, Kwong JC, Buckeridge DL. The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine. February 2012, s. 1255–64. DOI 10.1016/j.vaccine.2011.12.089. PMID 22214889. 
  • Thomas RE, Lorenzetti DL. Interventions to increase influenza vaccination rates of those 60 years and older in the community. The Cochrane Database of Systematic Reviews. May 2018, s. CD005188. DOI 10.1002/14651858.CD005188.pub4. PMID 29845606. 
  • ((Centers for Disease Control Prevention (CDC))). Update on influenza A (H1N1) 2009 monovalent vaccines. Morbidity and Mortality Weekly Report (MMWR). October 2009, s. 1100–01. Dostupné v archivu pořízeném z originálu dne June 29, 2011. PMID 19816398. 
  • La Torre G, Di Thiene D, Cadeddu C, Ricciardi W, Boccia A. Behaviours regarding preventive measures against pandemic H1N1 influenza among Italian healthcare workers, October 2009. Euro Surveillance. December 2009. PMID 20003908. 
  • Amodio E, Anastasi G, Marsala MG, Torregrossa MV, Romano N, Firenze A. Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy). Vaccine. February 2011, s. 1408–12. DOI 10.1016/j.vaccine.2010.12.041. PMID 21199700. 
  • Chor JS, Ngai KL, Goggins WB, Wong MC, Wong SY, Lee N, Leung TF, Rainer TH, Griffiths S, Chan PK. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ. August 2009, s. b3391. DOI 10.1136/bmj.b3391. PMID 19706937. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season. Morbidity and Mortality Weekly Report (MMWR). August 2011, s. 1073–77. Dostupné v archivu pořízeném z originálu dne May 25, 2017. PMID 21849963. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel: 2011–12 influenza season, United States. Morbidity and Mortality Weekly Report (MMWR). September 2012, s. 753–57. Dostupné v archivu pořízeném z originálu dne June 24, 2017. PMID 23013720. 
  • Bull AL, Bennett N, Pitcher HC, Russo PL, Richards MJ. Influenza vaccine coverage among health care workers in Victorian public hospitals. The Medical Journal of Australia. February 2007, s. 185–86. Dostupné online. DOI 10.5694/j.1326-5377.2007.tb00858.x. PMID 17309419. S2CID 25091208. 
  • Abbasi J. The Search for a Universal Flu Vaccine Heats Up. JAMA. November 2019, s. 1942–1944. DOI 10.1001/jama.2019.16816. PMID 31693060. S2CID 207903441. 
  • Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. May 2007, s. 3871–78. DOI 10.1016/j.vaccine.2007.01.106. PMID 17337102. 
  • Postma MJ, Baltussen RP, Palache AM, Wilschut JC. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. April 2006, s. 215–27. DOI 10.1586/14737167.6.2.215. PMID 20528557. S2CID 12765724. 
  • Newall AT, Kelly H, Harsley S, Scuffham PA. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. PharmacoEconomics. 2009, s. 439–50. DOI 10.2165/00019053-200927060-00001. PMID 19640008. S2CID 20855671. 
  • Newall AT, Viboud C, Wood JG. Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiology and Infection. June 2010, s. 836–42. Dostupné online. DOI 10.1017/S095026880999118X. PMID 19941685. S2CID 29939376. 
  • Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. PharmacoEconomics. August 2013, s. 693–702. DOI 10.1007/s40273-013-0060-7. PMID 23645539. S2CID 8616720. 
  • Newall AT, Scuffham PA. Uncertainty and variability in influenza cost-effectiveness models. Australian and New Zealand Journal of Public Health. December 2011, s. 576; author reply 576–77. DOI 10.1111/j.1753-6405.2011.00788.x. PMID 22151168. S2CID 22402257. 
  • Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations. Drugs. January 2012, s. 35–48. DOI 10.2165/11597310-000000000-00000. PMID 22191794. S2CID 46305863. 
  • Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. PharmacoEconomics. August 2012, s. 647–60. DOI 10.2165/11599130-000000000-00000. PMID 22788257. S2CID 38289883. 
  • Newall AT, Wood JG, Oudin N, MacIntyre CR. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerging Infectious Diseases. February 2010, s. 224–30. DOI 10.3201/eid1602.090571. PMID 20113551. 
  • Wagner M, Lampos V, Yom-Tov E, Pebody R, Cox IJ. Estimating the Population Impact of a New Pediatric Influenza Vaccination Program in England Using Social Media Content. Journal of Medical Internet Research. December 2017, s. e416. DOI 10.2196/jmir.8184. PMID 29269339. 
  • Cho A, Wrammert J. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Current Opinion in Virology. April 2016, s. 110–115. DOI 10.1016/j.coviro.2016.03.002. PMID 27031684. 
  • OCUNO, Y. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.. Journal of Virology. May 1993, s. 2552–58. DOI 10.1128/JVI.67.5.2552-2558.1993. PMID 7682624. 
  • Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. European Journal of Pharmaceutics and Biopharmaceutics. August 2015, s. 251–63. DOI 10.1016/j.ejpb.2015.05.023. PMID 26047796. 
  • Deng L, Cho KJ, Fiers W, Saelens X. M2e-Based Universal Influenza A Vaccines. Vaccines. February 2015, s. 105–36. DOI 10.3390/vaccines3010105. PMID 26344949. 
  • Gottlieb T, Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. Journal of Autoimmunity. November 2014, s. 15–20. DOI 10.1016/j.jaut.2014.07.005. PMID 25172355. 
  • Toussi DN, Massari P. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines. April 2014, s. 323–53. DOI 10.3390/vaccines2020323. PMID 26344622. 
  • Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. October 2014, s. 5816–23. DOI 10.1016/j.vaccine.2014.08.031. PMID 25173483. 
  • van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, Frijlink HW, Hak E. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol. Medicine (Baltimore). March 2017, s. e6339. DOI 10.1097/MD.0000000000006339. PMID 28296763. 
  • FAST, Patricia E; COX, Josephine H. An influenza vaccine pill-can we swallow it?. The Lancet Infectious Diseases. September 1, 2015, s. 1051–6; discussion 1056–57. Dostupné online [cit. January 27, 2020]. DOI 10.1016/s1473-3099(15)00252-2. PMID 2633331. 
  • LIEBOWITZ, David; GOTTLIEB, Keith; KOLHATKAR, Nikita S; GARG, Shaily J; ASHER, Jason M; NAZARENO, Jonathan. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. The Lancet Infectious Diseases. Elsevier, January 21, 2020, s. 435–444. Dostupné online [cit. January 27, 2020]. DOI 10.1016/S1473-3099(19)30584-5. PMID 31978354. S2CID 210892802. 
  • Yen HL, Peiris JS. Virology: bird flu in mammals. Nature. May 2012, s. 332–33. DOI 10.1038/nature11192. PMID 22722190. S2CID 205229301. Bibcode 2012Natur.486..332Y. 
  • Karaca K, Dubovi EJ, Siger L, Robles A, Audonnet JC, Jiansheng Y, Nordgren R, Minke JM. Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs. American Journal of Veterinary Research. February 2007, s. 208–12. DOI 10.2460/ajvr.68.2.208. PMID 17269888. 
  • Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 Influenza Season. MMWR. Recommendations and Reports. August 2017, s. 1–20. Dostupné online. DOI 10.15585/mmwr.rr6602a1. PMID 28841201. 
  • Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness – United States, February 2018. MMWR. Morbidity and Mortality Weekly Report. February 2018, s. 180–85. Dostupné online. DOI 10.15585/mmwr.mm6706a2. PMID 29447141. 
  • ((World Health Organization)). Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season. Wkly. Epidemiol. Rec.. October 2017, s. 625–33. PMID 29052409. 
  • ((World Health Organization)). Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Wkly. Epidemiol. Rec.. March 2018, s. 133–41. PMID 29569429. 

nih.gov

  • Priming with DNA vaccine makes avian flu vaccine work better (NIH News) [online]. October 3, 2011. Dostupné v archivu pořízeném z originálu dne September 27, 2012. 
  • NIH begins first-in-human trial of a universal influenza vaccine candidate [online]. April 3, 2019 [cit. 2019-11-12]. Dostupné v archivu pořízeném z originálu dne November 12, 2019. 

niaid.nih.gov

  • Influenza Genome Sequencing Project – Overview [online]. National Institutes of Health – National Institute of Allergy and Infectious Diseases [cit. 2013-05-27]. Dostupné v archivu pořízeném z originálu dne June 27, 2011. 

npr.org

  • GREENFIELDBOYCE, Nell. New and Old Ways to Make Flu Vaccines. [s.l.]: NPR, November 8, 2007. Dostupné v archivu pořízeném z originálu dne October 24, 2019. 

nsw.gov.au

health.nsw.gov.au

  • Influenza fact sheet [online]. Healthdirect, Department of Health, Government of Australia, April 1, 2019 [cit. 2019-05-29]. Dostupné online. 

nytimes.com

nytimes.com

well.blogs.nytimes.com

oecd.org

data.oecd.org

  • Health care use – Influenza vaccination rates – OECD Data [online]. [cit. 2020-04-24]. Dostupné online. 

path.org

  • Influenza Vaccine Strategies for Broad Global Access [online]. October 2007 [cit. 2009-09-16]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 

phac-aspc.gc.ca

  • ((National Advisory Committee on Immunization (NACI))). Statement on Seasonal Influenza Vaccine for 2012–2013. Canada Communicable Disease Report. Ottawa: August 2012. Dostupné v archivu pořízeném z originálu dne January 17, 2013. 

prnewswire.com

  • Novartis: Novartis receives FDA approval for Flucelvax, the first cell-culture vaccine in US to help protect against seasonal influenza, tisková zpráva, [cit. {{{accessdate}}}], Dostupné on-line.

publications.gc.ca

  • [s.l.]: [s.n.] Dostupné online. ISBN 978-1-100-24682-6. Cat.: HP40-117/2014E-PDF Pub.: 140118. 
  • GOVERNMENT OF CANADA, Public Services and Procurement Canada. Information archivée dans le Web. publications.gc.ca [online]. [cit. 2021-11-21]. Dostupné v archivu pořízeném z originálu dne 2022-01-19. 
  • An Advisory Committee Review National Advisory Committee on Immunization (NACI) [online]. Public Health Agency of Canada [cit. 2022-01-04]. Dostupné online. 

reuters.com

  • U.S. CDC director urges flu vaccinations as pediatric deaths mount. Reuters. 2018-01-22. Dostupné online [cit. 2021-11-19]. (anglicky) 

sahealth.sa.gov.au

  • Flu vaccine [online]. [cit. 2021-04-29]. Dostupné online. 

sanofi.us

news.sanofi.us

  • FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older - Nov 4, 2019. www.news.sanofi.us [online]. [cit. 2021-11-18]. Dostupné online. 

sciencebasedmedicine.org

  • High Dose Flu Vaccine for the Elderly | Science-Based Medicine. sciencebasedmedicine.org [online]. 2010-10-19 [cit. 2021-11-19]. Dostupné online. (anglicky) 

semanticscholar.org

api.semanticscholar.org

semanticscholar.org

seqirus.com

  • Seqirus: Seqirus receives FDA approval for Flucelvax Quadrivalent (Influenza Vaccine) for people four years of age and older, tisková zpráva, [cit. {{{accessdate}}}], Dostupné on-line. Archivovaná kopie. www.seqirus.com [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném z originálu dne 2017-01-16. 

seqirus.us

  • Seqirus Receives FDA Approval for FLUAD® Quadrivalent for Adults 65 Years and Older. www.seqirus.us [online]. [cit. 2021-11-18]. Dostupné online. (anglicky) 
  • Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market. www.seqirus.us [online]. [cit. 2021-11-18]. Dostupné online. (anglicky) 

tga.gov.au

  • Fluad Quad Australian prescription medicine decision summary [online]. December 13, 2019 [cit. 2020-08-24]. Dostupné online. 

theatlantic.com

  • LENZER, Shannon Brownlee, Jeanne. Does the Vaccine Matter?. The Atlantic [online]. 2009-11-01 [cit. 2021-11-18]. Dostupné online. (anglicky) 

theguardian.com

thelancet.com

  • FAST, Patricia E; COX, Josephine H. An influenza vaccine pill-can we swallow it?. The Lancet Infectious Diseases. September 1, 2015, s. 1051–6; discussion 1056–57. Dostupné online [cit. January 27, 2020]. DOI 10.1016/s1473-3099(15)00252-2. PMID 2633331. 
  • LIEBOWITZ, David; GOTTLIEB, Keith; KOLHATKAR, Nikita S; GARG, Shaily J; ASHER, Jason M; NAZARENO, Jonathan. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. The Lancet Infectious Diseases. Elsevier, January 21, 2020, s. 435–444. Dostupné online [cit. January 27, 2020]. DOI 10.1016/S1473-3099(19)30584-5. PMID 31978354. S2CID 210892802. 

uaeequafed.ae

  • UAE Equestrian & Racing Federation [online]. March 22, 2005. Dostupné v archivu pořízeném z originálu dne March 22, 2005. 

ucl.ac.uk

discovery.ucl.ac.uk

umn.edu

cidrap.umn.edu

  • SCHNIRRING, Lisa. CDC updates flu vaccination recommendations [online]. August 18, 2011 [cit. 2019-10-24]. Dostupné v archivu pořízeném z originálu dne October 25, 2019. 
  • ROOS, Robert. FDA approves first flu vaccine grown in insect cells [online]. October 14, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 
  • WHO switches H1N1 in Southern Hemisphere flu vaccine [online]. September 29, 2016 [cit. 2017-09-12]. Dostupné online. 

usnews.com

health.usnews.com

virology.ws

  • RACANIELLO, Vincent. Influenza virus growth in eggs [online]. Virology Blog, Dec 2009. Dostupné v archivu pořízeném z originálu dne December 25, 2014. 

washingtonpost.com

  • SUN, Lena H. This season's flu vaccine is only 36 percent effective, but experts say you should still get it. The Washington Post. February 15, 2018. Dostupné online [cit. February 17, 2018]. 

web.archive.org

  • https://web.archive.org/web/20130102094936/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm
  • https://web.archive.org/web/20130518014553/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm
  • https://web.archive.org/web/19991009112042/http://www.haverford.edu/biology/edwards/disease/viral_essays/warnervirus.htm
  • FDA approves first quadrivalent vaccine to prevent seasonal influenza. web.archive.org [online]. 2012-12-21 [cit. 2021-11-18]. Dostupné v archivu pořízeném z originálu dne 2012-12-21. 
  • GOVERNMENT OF CANADA, Public Services and Procurement Canada. Information archivée dans le Web. publications.gc.ca [online]. [cit. 2021-11-21]. Dostupné v archivu pořízeném z originálu dne 2022-01-19. 
  • FDA approves first seasonal influenza vaccine containing an adjuvant. web.archive.org [online]. 2017-07-22 [cit. 2021-11-20]. Dostupné v archivu pořízeném z originálu dne 2017-07-22. 
  • Fluad [online]. November 8, 2019 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. STN 125510. 
  • REINBERG, Steven. Last Year's H1N1 Flu Vaccine Was Safe, Study Finds. U.S. News & World Report. February 2, 2011. Dostupné v archivu pořízeném z originálu dne April 25, 2013. 
  • ((National Advisory Committee on Immunization (NACI))). Statement on Seasonal Influenza Vaccine for 2012–2013. Canada Communicable Disease Report. Ottawa: August 2012. Dostupné v archivu pořízeném z originálu dne January 17, 2013. 
  • Technical Report: Narcolepsy in association with pandemic influenza vaccination. Stockholm, Sweden: European Centre for Disease Prevention and Control (ECDC), 2012. Dostupné v archivu pořízeném z originálu dne December 31, 2013. ISBN 978-92-9193-388-4. 
  • Thimerosal in Flu Vaccine [online]. October 16, 2015 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. 
  • Thimerosal in Vaccines Thimerosal – Concerns – Vaccine Safety [online]. October 27, 2015 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne November 2, 2019. 
  • Global Advisory Committee on Vaccine Safety. Thiomersal and vaccines [online]. World Health Organization (WHO), July 14, 2006 [cit. 2007-11-20]. Dostupné v archivu pořízeném z originálu dne November 6, 2009. 
  • Vaccine use [online]. World Health Organization (WHO) [cit. 2017-01-15]. Dostupné v archivu pořízeném z originálu dne December 15, 2012. 
  • Influenza (Seasonal) Fact sheet [online]. World Health Organization (WHO), November 2016 [cit. 2017-01-15]. Dostupné v archivu pořízeném z originálu dne November 30, 2014. 
  • Archivovaná kopie. www.canada.ca [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném z originálu dne 2020-07-16. 
  • Risk groups for severe influenza [online]. [cit. 2019-10-22]. Dostupné v archivu pořízeném z originálu dne October 22, 2019. 
  • ECDC Reviews – New WHO recommendations on seasonal influenza .... European Centre for Disease Prevention and Control (ECDC). Dostupné v archivu pořízeném z originálu dne May 10, 2017. 
  • ECDC Guidance: Priority risk groups for influenza vaccination [online]. European Centre for Disease Prevention and Control (ECDC) [cit. 2016-12-25]. S. 7–8. Dostupné v archivu pořízeném z originálu dne December 25, 2016. 
  • Children & Influenza (Flu) [online]. U.S. Centers for Disease Control and Prevention (CDC), October 23, 2019. Dostupné v archivu pořízeném z originálu dne November 11, 2019. 
  • Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) [online]. September 16, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 
  • Influenza Vaccination: A Summary for Clinicians – Health Professionals – Seasonal Influenza (Flu) [online]. U.S. Centers for Disease Control and Prevention (CDC), September 6, 2018. Dostupné v archivu pořízeném z originálu dne February 24, 2008. 
  • TANNER, Lindsey. Hospitals crack down on workers who refuse flu shots [online]. NBC News, January 13, 2013 [cit. 2014-07-24]. Dostupné v archivu pořízeném z originálu dne December 3, 2013. 
  • ((Centers for Disease Control Prevention (CDC))). Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season. Morbidity and Mortality Weekly Report (MMWR). December 2010, s. 1541–45. Dostupné v archivu pořízeném z originálu dne June 25, 2017. PMID 21124293. 
  • ALTMAN, Lawrence K. Panel Advises Flu Shots for Children Up to Age 18. The New York Times. February 28, 2008. Dostupné v archivu pořízeném z originálu dne January 22, 2015. 
  • Immunization Schedules [online]. U.S. Centers for Disease Control and Prevention (CDC) [cit. 2014-11-04]. Dostupné v archivu pořízeném z originálu dne November 5, 2014. 
  • ((Centers for Disease Control Prevention (CDC))). Update on influenza A (H1N1) 2009 monovalent vaccines. Morbidity and Mortality Weekly Report (MMWR). October 2009, s. 1100–01. Dostupné v archivu pořízeném z originálu dne June 29, 2011. PMID 19816398. 
  • SCHNIRRING, Lisa. CDC updates flu vaccination recommendations [online]. August 18, 2011 [cit. 2019-10-24]. Dostupné v archivu pořízeném z originálu dne October 25, 2019. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season. Morbidity and Mortality Weekly Report (MMWR). August 2011, s. 1073–77. Dostupné v archivu pořízeném z originálu dne May 25, 2017. PMID 21849963. 
  • ((Centers for Disease Control Prevention (CDC))). Influenza vaccination coverage among health-care personnel: 2011–12 influenza season, United States. Morbidity and Mortality Weekly Report (MMWR). September 2012, s. 753–57. Dostupné v archivu pořízeném z originálu dne June 24, 2017. PMID 23013720. 
  • GREENFIELDBOYCE, Nell. New and Old Ways to Make Flu Vaccines. [s.l.]: NPR, November 8, 2007. Dostupné v archivu pořízeném z originálu dne October 24, 2019. 
  • Influenza Vaccine Strategies for Broad Global Access [online]. October 2007 [cit. 2009-09-16]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 
  • how it's made [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném dne July 5, 2010. 
  • Influenza vaccine viruses and reagents [online]. World Health Organization (WHO). Dostupné v archivu pořízeném z originálu dne May 27, 2013. 
  • Recommendations for the production and control of influenza vaccine (inactivated) [online]. World Health Organization (WHO) [cit. 2013-05-27]. Dostupné v archivu pořízeném z originálu dne October 28, 2013. 
  • RACANIELLO, Vincent. Influenza virus growth in eggs [online]. Virology Blog, Dec 2009. Dostupné v archivu pořízeném z originálu dne December 25, 2014. 
  • IZZAT, Fakhrul. Viral Cultivation in Chicken Embryo [online]. Youtube, Apr 2012. Dostupné v archivu pořízeném z originálu dne May 26, 2015. 
  • How Influenza (Flu) Vaccines Are Made [online]. U.S. Centers for Disease Control and Prevention (CDC), November 26, 2019 [cit. 2019-12-02]. Dostupné v archivu pořízeném z originálu dne December 2, 2019. 
  • Priming with DNA vaccine makes avian flu vaccine work better (NIH News) [online]. October 3, 2011. Dostupné v archivu pořízeném z originálu dne September 27, 2012. 
  • RESEARCH, Center for Biologics Evaluation and. Approved Products – November 20, 2012 Approval Letter – Flucelvax [online]. U.S. Food and Drug Administration (FDA). Dostupné v archivu pořízeném z originálu dne December 3, 2012. 
  • Seqirus: Seqirus receives FDA approval for Flucelvax Quadrivalent (Influenza Vaccine) for people four years of age and older, tisková zpráva, [cit. {{{accessdate}}}], Dostupné on-line. Archivovaná kopie. www.seqirus.com [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném z originálu dne 2017-01-16. 
  • ROOS, Robert. FDA approves first flu vaccine grown in insect cells [online]. October 14, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. 
  • Flublok [online]. February 26, 2018 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. STN 125285. 
  • Flublok Quadrivalent [online]. August 2, 2019 [cit. 2019-10-14]. Dostupné v archivu pořízeném z originálu dne October 14, 2019. STN 125285. 
  • Influenza Genome Sequencing Project – Overview [online]. National Institutes of Health – National Institute of Allergy and Infectious Diseases [cit. 2013-05-27]. Dostupné v archivu pořízeném z originálu dne June 27, 2011. 
  • Acute Respiratory Infections (Update September 2009) [online]. World Health Organization (WHO), September 2009 [cit. 2009-09-16]. Dostupné v archivu pořízeném z originálu dne September 29, 2009. 
  • Tables on the Clinical trials of pandemic influenza prototype vaccines [online]. World Health Organization (WHO), July 2009 [cit. 2009-09-21]. Dostupné v archivu pořízeném z originálu dne March 6, 2009. 
  • FDA Approves Vaccines for 2009 H1N1 Influenza Virus. web.archive.org [online]. 2009-10-15 [cit. 2021-11-20]. Dostupné v archivu pořízeném z originálu dne 2009-10-15. 
  • NIH begins first-in-human trial of a universal influenza vaccine candidate [online]. April 3, 2019 [cit. 2019-11-12]. Dostupné v archivu pořízeném z originálu dne November 12, 2019. 
  • Influenza Report (online book) Archivováno 10. 5. 2016 na Wayback Machine. chapter Avian Influenza by Timm C. Harder and Ortrud Werner
  • equiflunet_vaccines. 195.224.162.216 [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném dne 2006-01-10. 
  • UAE Equestrian & Racing Federation [online]. March 22, 2005. Dostupné v archivu pořízeném z originálu dne March 22, 2005. 
  • FEI guidelines [online]. Dostupné v archivu pořízeném z originálu dne October 26, 2007. 
  • MCNEIL, Donald G. Jr. Turning to Chickens in Fight With Bird Flu. The New York Times. May 2, 2006. Dostupné v archivu pořízeném z originálu dne November 14, 2012. 
  • Bird flu warning over partial protection of flocks [online]. August 16, 2006 [cit. 2021-11-22]. Dostupné v archivu pořízeném dne September 26, 2007. 
  • FAO Recommendations on the Prevention, Control and Eradication of Highly Pathogenic Avian Influenza (HPAI) in Asia [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném dne February 2, 2010. 
  • Swine Flu Virus Turns Endemic [online]. September 15, 2007. Dostupné v archivu pořízeném z originálu dne April 29, 2009. 
  • Custom Vaccines: Swine [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném dne April 30, 2009. 
  • Global influenza surveillance [online]. Dostupné v archivu pořízeném z originálu dne April 30, 2003. 
  • BROWN, David. Keeping ahead of flu comes down to guessing game. Knoxville News Sentinel. February 18, 2008. Dostupné v archivu pořízeném z originálu dne January 11, 2009. 
  • Influenza Virus Vaccine for the 2018–2019 Season [online]. November 8, 2018 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Influenza Vaccine for the 2019-2020 Season [online]. December 5, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Vaccines and Related Biological Products Advisory Committee March 6–7, 2019 Meeting Announcement [online]. March 6–7, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Vaccines and Related Biological Products Advisory Committee March 22, 2019 Meeting Announcement [online]. March 22, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • EU recommendations for 2019/2020 seasonal flu vaccine composition [online]. May 15, 2019 [cit. 2019-12-09]. Dostupné v archivu pořízeném z originálu dne December 10, 2019. 
  • Archivovaná kopie. www.ema.europa.eu [online]. [cit. 2021-11-22]. Dostupné v archivu pořízeném z originálu dne 2021-06-30. 

who.int

who.int

  • Influenza (Seasonal). www.who.int [online]. [cit. 2021-11-19]. Dostupné online. (anglicky) 
  • Global Advisory Committee on Vaccine Safety. Thiomersal and vaccines [online]. World Health Organization (WHO), July 14, 2006 [cit. 2007-11-20]. Dostupné v archivu pořízeném z originálu dne November 6, 2009. 
  • Vaccine use [online]. World Health Organization (WHO) [cit. 2017-01-15]. Dostupné v archivu pořízeném z originálu dne December 15, 2012. 
  • Influenza (Seasonal) Fact sheet [online]. World Health Organization (WHO), November 2016 [cit. 2017-01-15]. Dostupné v archivu pořízeném z originálu dne November 30, 2014. 
  • Influenza vaccine viruses and reagents [online]. World Health Organization (WHO). Dostupné v archivu pořízeném z originálu dne May 27, 2013. 
  • Recommendations for the production and control of influenza vaccine (inactivated) [online]. World Health Organization (WHO) [cit. 2013-05-27]. Dostupné v archivu pořízeném z originálu dne October 28, 2013. 
  • Acute Respiratory Infections (Update September 2009) [online]. World Health Organization (WHO), September 2009 [cit. 2009-09-16]. Dostupné v archivu pořízeném z originálu dne September 29, 2009. 
  • Tables on the Clinical trials of pandemic influenza prototype vaccines [online]. World Health Organization (WHO), July 2009 [cit. 2009-09-21]. Dostupné v archivu pořízeném z originálu dne March 6, 2009. 
  • Global Influenza Surveillance and Response System (GISRS) [online]. World Health Organization [cit. 2019-10-22]. Dostupné online. 
  • Spotlight: Influenza [online]. World Health Organization [cit. 2019-10-22]. Dostupné online. 
  • Global influenza surveillance [online]. Dostupné v archivu pořízeném z originálu dne April 30, 2003. 
  • Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season [online]. World Health Organization (WHO), September 28, 2017 [cit. 2017-09-28]. Dostupné online. 
  • Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season [online]. World Health Organization (WHO), February 22, 2018 [cit. 2018-09-12]. Dostupné online. 
  • Standardization of terminology of the pandemic A(H1N1) 2009 virus [online]. World Health Organization (WHO) [cit. 2012-06-14]. Dostupné online. 
  • Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season [online]. World Health Organization (WHO) [cit. 2019-03-22]. Dostupné online. 
  • Recommended composition of influenza virus vaccines for use in the 2020–2021 northern hemisphere influenza season [online]. February 28, 2020 [cit. 2020-08-25]. Dostupné online. 
  • Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season [online]. September 25, 2020 [cit. 2021-04-29]. Dostupné online. 

apps.who.int

  • WORLD HEALTH ORGANIZATION. Vaccines against influenza WHO position paper — November 2012 = Note de synthèse de l’OMS concernant les vaccins antigrippaux — novembre 2012. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. 2012, roč. 87, čís. 47, s. 461–476. Dostupné online [cit. 2021-11-16]. (anglicky) 
  • WORLD HEALTH ORGANIZATION. The immunological basis for immunization series: module 23: influenza vaccines. [s.l.]: World Health Organization 63 s. Dostupné online. ISBN 978-92-4-151305-0. (anglicky) 

euro.who.int

  • Recommendations on influenza vaccination during the 2019–2020 winter season [online]. September 24, 2019 [cit. 2019-10-14]. Dostupné online. 

worldcat.org

youtube.com

  • IZZAT, Fakhrul. Viral Cultivation in Chicken Embryo [online]. Youtube, Apr 2012. Dostupné v archivu pořízeném z originálu dne May 26, 2015. 

zenodo.org

  • Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. March 2009, s. 2114–20. Dostupné online. DOI 10.1016/j.vaccine.2009.01.125. PMID 19356614.